<DOC>
	<DOCNO>NCT00004887</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . It yet know whether paclitaxel carboplatin effective standard chemotherapy advance non-small cell lung cancer . PURPOSE : Randomized phase III trial compare effectiveness paclitaxel carboplatin chemotherapy standard chemotherapy treat patient stage III stage IV non-small cell lung cancer remove surgery .</brief_summary>
	<brief_title>Paclitaxel Carboplatin Chemotherapy Compared With Standard Chemotherapy Treating Patients With Stage III Stage IV Non-small Cell Lung Cancer That Can Be Removed During Surgery</brief_title>
	<detailed_description>OBJECTIVES : - Compare one two year survival patient inoperable advanced non-small cell lung cancer treat paclitaxel cisplatin versus standard platinum therapy . - Compare toxic effect two regimen patient population . - Compare performance status , tumor response , quality life patient treatment regimen . OUTLINE : This randomize , multicenter study . Patients stratify accord center , stage disease ( IIIA vs IIIB v IV ) , performance status ( ECOG O vs 1 v 2 v 3 ) . Patients randomize one two treatment arm : - Arm I : Patients receive paclitaxel IV 3 hour , follow carboplatin IV 30 minute day 1 . - Arm II : Patients receive mitomycin IV , ifosfamide IV 3 hour , cisplatin IV 1 hour day 1 OR mitomycin IV , vinblastine IV , cisplatin IV 4 hour day 1 . Treatment continue every 3 week 4 course absence disease progression unacceptable toxicity . Quality life assess treatment course . Patients follow survival . PROJECTED ACCRUAL : Approximately 300 patient ( 150 per treatment arm ) accrue study .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Mitomycin</mesh_term>
	<mesh_term>Mitomycins</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm inoperable advanced nonsmall cell lung cancer Stage IIIA , IIIB , IV Not eligible curative radiotherapy surgery Measurable evaluable disease No bony lesion site measurable disease No symptomatic brain metastasis PATIENT CHARACTERISTICS : Age : Over 18 Performance status : ECOG 02 ( ECOG 3 allow case ) Life expectancy : At least 12 week Hematopoietic : WBC least 3,000/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin great 2 time upper limit normal ( ULN ) AST ALT great 3 time ULN ( great 5 time ULN liver metastasis ) Renal : Creatinine normal OR Creatinine clearance least 60 mL/min Other : Not pregnant Fertile patient must use effective contraception 3 month study No active infection No serious systemic disorder would preclude compliance No second malignancy except carcinoma situ cervix adequately treat basal cell skin cancer No peripheral neuropathy , significant neurological disorder ( e.g. , seizure ) , psychiatric disorder PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy Endocrine therapy : Not specify Radiotherapy : See Disease Characteristics Prior radiotherapy allow measurable disease outside irradiated field Surgery : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2000</verification_date>
	<keyword>stage IIIA non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
</DOC>